Alzamend Neuro, Inc. announced that it is partnering with Biorasi as its contract research organization (“CRO”) to conduct a first-in-human, randomized, double-blind, placebo-controlled, parallel group, phase I/IIA study to assess the safety, tolerability, and efficacy of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia of the Alzheimer's type. The purpose of this trial will be to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared with that of placebo in 20-30 subjects with mild-to-moderate dementia of the Alzheimer's type. Also, the trial will be designed to determine the optimal dosage of ALZN002 for treatment of patients with Alzheimer's in a larger Phase IIB efficacy and safety clinical trial (ALZN002-02), which Alzamend expects to initiate within three months of receiving data from the initial trial.

ALZN002 is a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.